BioArctic Hits Milestone as Leqembi Sales Surge, but FDA Review Delay Looms
Event summary
- Leqembi sales exceeded EUR 500M in Eisai's fiscal year 2025, triggering a EUR 20M milestone payment to BioArctic.
- FDA granted Priority Review for Leqembi Iqlik™ subcutaneous formulation but extended review period by three months.
- Eisai forecasted JPY 143.5B (SEK 8.4B) in Leqembi sales for fiscal year 2026, a 63% year-over-year growth.
- Swedish NT Council declined to recommend Leqembi for Swedish healthcare.
- BioArctic's Q1 2026 net revenues reached SEK 437.6M, with SEK 160.8M from Leqembi royalties.
The big picture
BioArctic's strong financial performance underscores Leqembi's commercial success, but regulatory hurdles and market access challenges highlight the complexities of rolling out Alzheimer's treatments. The company's focus on expanding its BrainTransporter platform positions it for long-term growth beyond Leqembi, though execution risks remain. Eisai's aggressive sales forecast suggests sustained momentum, but BioArctic must navigate varying regulatory landscapes to maximize Leqembi's global potential.
What we're watching
- Regulatory Timelines
- Whether the FDA's three-month extension for Leqembi Iqlik™ review will impact commercialization plans.
- Market Expansion
- How BioArctic will navigate the Swedish NT Council's decision to exclude Leqembi from healthcare.
- Pipeline Progress
- The pace at which BioArctic advances its BrainTransporter technology and Parkinson's-related programs.
Related topics